Serina Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on June 17, 2026, regarding Serina Therapeutics, Inc. (NYSE American: SER). The filing details the results of the Company's 2026 Annual Meeting of Stockholders and the subsequent amendment to its Certificate of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Corporate Actions
- Authorized Share Increase: Effective June 17, 2026, the Company increased its authorized common stock from 40,000,000 to 125,000,000 shares.
- Equity Plan Amendment: Stockholders approved an increase of 2,000,000 shares available for issuance under the 2024 Equity Incentive Plan.
- Director Elections: Gregory H. Bailey, M.D., Richard Marshall, CBE, M.D., Ph.D., and Jay Venkatesan, M.D. were elected to the Board of Directors.
- Capital Structure Approvals: Stockholders approved the conversion of Series A Preferred Stock to common stock and the issuance of common stock related to Private Placement Securities.
- Auditor Ratification: Frazier & Deeter, LLC was ratified as the independent registered public accounting firm for the 2026 fiscal year.
Management Commentary and Risks
The filing contains no management commentary on operational outlook, risks, contingencies, or unusual items. The document strictly reports on the procedural outcomes of the Annual Meeting and the legal effect of the Certificate of Amendment.
Investor Verification Checklist
- Verify the impact of the 85,000,000 share increase in authorized capital on potential future dilution.
- Review the full text of the Certificate of Amendment (Exhibit 3.1) for specific terms regarding the share increase.
- Confirm the details of the 2,000,000 share increase to the 2024 Equity Incentive Plan (Exhibit 10.1).
- Check subsequent filings for the actual issuance of shares related to the approved Preferred Stock conversion and Private Placement exercises.